Web22 uur geleden · April 13, 2024 By Nuala Moran Alentis Therapeutics SA has closed a $105 million series C round which will fund simultaneous phase II and phase Ib trials of anti-Claudin-1 antibodies in the treatment of organ fibrosis and phase I development in fibrosis-associated cancers. WebBy Nuala Moran BioWorld Pfizer Inc.’s appetite for acquisitions shows no signs of abating as it announced this morning its plan to acquire biotech Seagen Inc. for a whopping $43 …
Nuala Moran BioWorld
Web10 apr. 2024 · By Nuala Moran Two years after its formation, Mosaic Therapeutics Ltd. has raised $28 million in a series A to begin commercialization of research carried out by the Translational Cancer Genomics Lab at the Sanger Institute in Cambridge, U.K., into the genetic vulnerabilities of multiple tumor types and how that impacts response to therapy. WebGreat article by Nuala Moran in Clarivate #BioWorld on the unveiling of our pipeline of small molecule drug programs and the drug discovery platform… Liked by Edward … hot springs hideout thermopolis
Crick researchers get OK for gene editing on human embryos
Web8 apr. 2024 · Nuala Moran / BioWorld. LONDON – The largest study to date, involving 236,379 confirmed cases, shows that one in three survivors of COVID-19 was diagnosed … WebByNuala Moran No Comments LONDON – In the largest-ever series A for a Spanish biotech, Splicebio S.L. has raised €50 million (US$56.9 million) to apply its protein … WebBy Nuala Moran, Staff Writer LONDON – Engitix Ltd. has raised £5 million (US$6.4 million) in a series A to flip the business model from drug discovery services to drug … line drawing of a woman\u0027s buttocks